
Traws Pharma, Inc. has deferred a planned Phase 2a human influenza challenge study of tivoxavir marboxil, known as TXM, following a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).
In its June 12, 2026 announcement, the company said influenza treatment and prevention remain a priority. It is advancing alternative antiviral candidates intended to preserve TXM’s long-lasting activity while avoiding mutagenic potential.
TXM Shows Activity in Bird Flu Animal Studies
C. David Pauza, PhD, Chief Science Officer at Traws Pharma, said TXM demonstrated potent efficacy in three animal models of highly pathogenic avian influenza. He also described the candidate’s pharmacokinetic profile as consistent with potential use in bird flu treatment and prevention.
These are company-reported animal findings, not results from the planned human influenza challenge study. Pauza said TXM retains potential for emergency use during a bird flu outbreak and for prevention in high-risk populations. His comments describe possible future applications rather than an authorized use.
Alternative Influenza Candidates Are Advancing
Traws Pharma said it has a portfolio of backup influenza antiviral compounds. The company is advancing candidates designed to maintain TXM’s long-duration pharmacokinetic and antiviral characteristics while avoiding mutagenic potential.
Chief Executive Officer Iain Dukes said the regulatory feedback affects the timing of the planned challenge study but does not change the company’s confidence in the underlying scientific rationale. He also highlighted the potential role of long-acting antivirals in seasonal influenza prevention.
Influenza Prevention Remains a Research Priority
Robert R. Redfield, MD, Chief Medical Officer at Traws Pharma and former Director of the U.S. Centers for Disease Control and Prevention, described influenza, including bird flu, as a continuing public health threat.
While acknowledging the setback involving TXM, Redfield emphasized the importance of treatment and prevention for older adults and people with weakened immune systems, who face a greater risk of severe influenza.
Company Expects Funding to Support Operations Into Q1 2027
Dukes said Traws Pharma’s cash runway extended into the first quarter of 2027. This estimate reflected management’s expectations at the time of the June announcement.
The company plans to continue developing alternative influenza candidates while addressing potential regulatory concerns. Its forward-looking disclosures identify risks that could affect development, including regulatory decisions and its ability to advance drug candidates.
Separately, those disclosures reference an existing U.S. Food and Drug Administration clinical hold associated with TXM’s Investigational New Drug filing. That U.S. regulatory matter is distinct from the MHRA review that prompted the deferral of the planned UK challenge study.
About Traws Pharma
Traws Pharma is a clinical-stage biopharmaceutical company based in Newtown, Pennsylvania. It develops investigational oral small-molecule antiviral medicines targeting difficult-to-treat or resistant viral strains.
Its development activities address seasonal influenza, H5N1 bird flu, COVID-19, and Long COVID, as well as potential treatments for Hantavirus infections, Ebola virus disease, and Lassa fever. The company combines antiviral drug development, medical intelligence, and regulatory strategy in its research programs.

